Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/incannex-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:10095:1" rel="noopener">Incannex Healthcare (IHL AU)</a> has a differentiated product portfolio, addressing unmet global medical needs. With cash balance of A$37.5 million, Incannex is well-resourced to fund its activities for ~2.5 years.</li>
<li>Recently completed acquisition of APIRx Pharmaceuticals has strategically expanded intellectual property portfolio to 28 clinical programs, the world’s largest portfolio of patented medicinal cannabinoid drug formulations and psychedelic treatment protocols.</li>
<li>The combined annual global market size of the targeted indications is over $420 billion. The company’s strategy of combining cannabinoids with FDA-approved generic drugs calls for shorter regulatory pathway.</li>
</ul>



Incannex Healthcare (IHL AU) has a differentiated product portfolio, addressing unmet global medical needs. With cash balance of A$37.5 million, Incannex is well-resourced to fund its activities for ~2.5 years.
Recently completed acquisition of APIRx Pharmaceuticals has strategically expanded intellectual property portfolio to 28 clinical programs, the world’s largest portfolio of patented medicinal cannabinoid drug formulations and psychedelic treatment protocols.
The combined annual global market size of the targeted indications is over $420 billion. The company’s strategy of combining cannabinoids with FDA-approved generic drugs calls for shorter regulatory pathway.


Incannex Healthcare (IHL AU): Attractive Idea Backed by Niche Focus on Cannabinoid Pharmaceuticals

SK Biopharmaceuticals   / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals Co Ltd (326030 KS)</a> surpassed KRW400 billion sales last year, the highest since inception. The company targets more than doubling sales this year, through global expansion of cenobamate.</li>
<li>The company is expected to launch its third commercial drug, carisbamate (currently in phase 3 trial) in global market in 2025.  </li>
<li>On the back of robust 2021 financial performance, SK Biopharmaceuticals shares have recovered and reached to two-month high, thereby offering an attractive and confirming buying opportunity.</li>
</ul>



SK Biopharmaceuticals Co Ltd (326030 KS) surpassed KRW400 billion sales last year, the highest since inception. The company targets more than doubling sales this year, through global expansion of cenobamate.
The company is expected to launch its third commercial drug, carisbamate (currently in phase 3 trial) in global market in 2025.  
On the back of robust 2021 financial performance, SK Biopharmaceuticals shares have recovered and reached to two-month high, thereby offering an attractive and confirming buying opportunity.


SK Biopharmaceuticals (326030 KS): Highest Performance in 2021; Pipeline Progress Entails Visibility

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Legal and regulatory changes have spawned cannabis companies, focused on cannabis-based medical and recreational products and the development of new breeds of crop </li>
<li>In Cannabis innovations <a href="https://www.smartkarma.com/entities/philip-morris-international" target="_blank" data-smartkarma-citation="entities:13328:1" rel="noopener">Philip Morris International (PM US)</a>, <a href="https://www.smartkarma.com/entities/canopy-growth-corp" target="_blank" data-smartkarma-citation="entities:25083:1" rel="noopener">Canopy Growth (WEED CN)</a>, <a href="https://www.smartkarma.com/entities/jazz-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:15881:1" rel="noopener">Jazz Pharmaceuticals (JAZZ US)</a><a href="https://www.smartkarma.com/entities/merck-co-inc" target="_blank" data-smartkarma-citation="entities:1130:1" rel="noopener">Merck &amp; Co Inc. (MRK US)</a> and <a href="https://www.smartkarma.com/entities/takeda-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:11747:1" rel="noopener">Takeda Pharmaceutical (4502 JP)</a> lead</li>
<li>In overall plant-based extracts innovations <a href="https://www.smartkarma.com/entities/jazz-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:15881:1" rel="noopener">Jazz Pharmaceuticals (JAZZ US)</a>, <a href="https://www.smartkarma.com/entities/eid-parry-india-ltd" target="_blank" data-smartkarma-citation="entities:6925:1" rel="noopener">Eid Parry India (EID IN)</a>, <a href="https://www.smartkarma.com/entities/abbott-laboratories" target="_blank" data-smartkarma-citation="entities:11987:1" rel="noopener">Abbott Laboratories (ABT US), </a>Indena, Mars Incorporated, and Liveleaf are the leaders.</li>
</ul>


Legal and regulatory changes have spawned cannabis companies, focused on cannabis-based medical and recreational products and the development of new breeds of crop 
In Cannabis innovations Philip Morris International (PM US), Canopy Growth (WEED CN), Jazz Pharmaceuticals (JAZZ US)Merck &amp; Co Inc. (MRK US) and Takeda Pharmaceutical (4502 JP) lead
In overall plant-based extracts innovations Jazz Pharmaceuticals (JAZZ US), Eid Parry India (EID IN), Abbott Laboratories (ABT US), Indena, Mars Incorporated, and Liveleaf are the leaders.


Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-biopharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:28966:1" rel="noopener">SK Biopharmaceuticals Co Ltd (326030 KS)</a> has two marketed drugs for central nervous system disorders. Last year, the company launched its independently developed drug Xcopri (cenobamate) in the U.S.</li>
<li>The company has initiated phase 3 clinical trial for Xcopri in Asia in sync with its objective to expand beyond the U.S. and to enhance presence in Asia.</li>
<li>SK Biopharmaceuticals entered into greater China and acquired a 45% stake in Ignis Therapeutics through out-licensing six of its clinical pipelines.</li>
</ul>



SK Biopharmaceuticals Co Ltd (326030 KS) has two marketed drugs for central nervous system disorders. Last year, the company launched its independently developed drug Xcopri (cenobamate) in the U.S.
The company has initiated phase 3 clinical trial for Xcopri in Asia in sync with its objective to expand beyond the U.S. and to enhance presence in Asia.
SK Biopharmaceuticals entered into greater China and acquired a 45% stake in Ignis Therapeutics through out-licensing six of its clinical pipelines.


SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders

<p>Takeda’s stock plunged 12% in last one year to trade near its 52-week low. On October 6, the company halted two phase 2 clinical trials of TAK-994 after safety signal emerged in the trials. Although it is still not clear whether TAK-994 will be discontinued, Takeda’s share price declined ~11% following the news. With forthcoming patent expiry of some key drugs, this setback on a heavyweight neuroscience pipeline leads to a jittery outlook for the company, at least in near-term. TAK-994 has the potential to become a blockbuster drug for the company, if approved. Takeda’s top selling gastroenterology drug Entyvio (2020 revenue ¥429 billion) is patent protected through May 2026, while its neuroscience drug Vyvanse’s (2020 revenue ¥272 billion) patent will expire in February 2023 in the U.S. Both the drugs report mid to high-teen percentage growth in revenue. The current pipeline lacks multiple late-stage candidates, which are likely to compensate for the patent cliff to be faced by Takeda.    </p>

Takeda’s stock plunged 12% in last one year to trade near its 52-week low. On October 6, the company halted two phase 2 clinical trials of TAK-994 after safety signal emerged in the trials. Although it is still not clear whether TAK-994 will be discontinued, Takeda’s share price declined ~11% following the news. With forthcoming patent expiry of some key drugs, this setback on a heavyweight neuroscience pipeline leads to a jittery outlook for the company, at least in near-term. TAK-994 has the potential to become a blockbuster drug for the company, if approved. Takeda’s top selling gastroenterology drug Entyvio (2020 revenue ¥429 billion) is patent protected through May 2026, while its neuroscience drug Vyvanse’s (2020 revenue ¥272 billion) patent will expire in February 2023 in the U.S. Both the drugs report mid to high-teen percentage growth in revenue. The current pipeline lacks multiple late-stage candidates, which are likely to compensate for the patent cliff to be faced by Takeda.    

Takeda Pharmaceutical (4502 JP): Recent Pipeline Blues Puts a Brake on Stock Recovery

Ireland

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jazz Pharmaceuticals (JAZZ US)

Incannex Healthcare (IHL AU): Attractive Idea Backed by Niche Focus on Cannabinoid Pharmaceuticals

Incannex has 28+ drug candidates for broad range of under-met medical conditions representing major economic opportunities. The company is well...

Tina Banerjee

SK Biopharmaceuticals (326030 KS): Highest Performance in 2021; Pipeline Progress Entails Visibility

SKBP turned profitable in 2021 to report highest performance since its foundation. Geographic expansion of cenobamate and pipeline progress enhance...

Tina Banerjee

Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

Herbal medicinal and nutraceutical extracts are seen as instruments to maintain health and treat some conditions. Cannabis, in particular, will see...

Pyari Menon

SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders

SKBP's independently developed and marketed drug Xcopri has the potential to reach peak revenue of $1.5 billion in 2027. The company targets to...

Tina Banerjee

Takeda Pharmaceutical (4502 JP): Recent Pipeline Blues Puts a Brake on Stock Recovery

Takeda's shares are trading near 52-week low. Recent pipeline setback makes the near-term outlook jittery for the company.

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)